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H I G H L I G H T S
• Animal experiments are indispensable proof-of-principle evaluation of new, infection-control strategies.
• Morbidity and mortality must be mimicked in animal infection models in order to better predict human clinical outcome.
• Prevention of death and recurrence must be primary eﬃcacy targets in animal infection models.
• Secondary eﬃcacy targets indirectly relevant for infection-control must not be pursued at the expense of animal lives.
• Exploring mechanisms of action for infection-control strategies must only be done in vitro, but not in animal models.
A R T I C L E I N F O
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A B S T R A C T
Preventing bacterial infections from becoming the leading cause of death by the year 2050 requires the de-
velopment of novel, infection-control strategies, building heavily on biomaterials science, including nano-
technology. Pre-clinical (animal) studies are indispensable for this development. Often, animal infection out-
comes bear little relation to human clinical outcome. Here, we review conclusions from pathogen-inoculum
dose-ﬁnding pilot studies for evaluation of novel infection-control strategies in murine models. Pathogen-in-
oculum doses are generally preferred that produce the largest diﬀerences in quantitative infection outcome
parameters between a control and an experimental group, without death or termination of animals due to having
reached an inhumane end-point during the study. However, animal death may represent a better end-point for
evaluation than large diﬀerences in outcome parameters or number of days over which infection persists. The
clinical relevance of lower pre-clinical outcomes, such as bioluminescence, colony forming units (CFUs) re-
trieved or more rapid clearance of infection is unknown, as most animals cure infection without intervention,
https://doi.org/10.1016/j.biomaterials.2019.119737
Received 7 October 2019; Received in revised form 2 December 2019; Accepted 25 December 2019
∗ Corresponding author.
∗∗ Corresponding author.
E-mail addresses: h.j.busscher@umcg.nl (H.J. Busscher), h.c.van.der.mei@umcg.nl (H.C. van der Mei).
Biomaterials 232 (2020) 119737
Available online 28 December 2019
0142-9612/ © 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
depending on pathogen-species and pathogen-inoculum dose administered. In human clinical practice, patients
suﬀering from infection present to hospital emergency wards, frequently in life-threatening conditions. Animal
infection-models should therefore use prevention of death and recurrence of infection as primary eﬃcacy targets
to be addressed by novel strategies. To compensate for increased animal morbidity and mortality, animal ex-
periments should solely be conducted for pre-clinical proof of principle and safety. With the advent of sophis-
ticated in vitro models, we advocate limiting use of animal models when exploring pathogenesis or infection
mechanisms.
1. Introduction
Infection is predicted to become the leading cause of death by the
year 2050 [1], a prediction which is predominantly due to the devel-
opment of infections by antimicrobial-resistant pathogens [2]. Pre-
venting this forecast from becoming clinical reality requires increased
development of novel infection-control strategies [3], i.e. strategies
aimed to treat (therapeutic-mode) or prevent (prophylactic-mode)
bacterial infection. Development pathways currently combine drug
development and administration with biomaterials science [4] and
nanotechnology [3]. Human clinical trials are required as the ﬁnal step
in introducing new drugs to the market [5]. However, human clinical
trials are costly [5] and often require enrollment of large numbers of
patients in control and experimental groups [6]. Deliberately infecting
human volunteers with an antibiotic-resistant pathogen is an ethically
unacceptable pathway to conduct human clinical trials, as has been
done for instance, in the so-called “Elek-experiment”. The Elek-ex-
periment [7] was ﬁrst described in 1957 in an era during which the
faith in newly discovered penicillin was unlimited [8] and deliberately
infecting human volunteers for scientiﬁc reasons was therefore con-
sidered acceptable. The Elek clinical trial focused on a speciﬁcally hard-
to-treat infection associated with an implanted biomaterial [9,10]. In a
biomaterial-associated infection, bacteria reside in a bioﬁlm-mode of
growth, providing pathogen protection against host immune responses
and other environmental threats, such as posed by antibiotics. Elek and
Conen [7] soaked sutures in a staphylococcal suspension, after which
volunteers received three infected sutures in the thigh: two stitches
were tied within the thigh, while a third stitch was pulled through the
skin and removed. After 24 h, volunteers became very ill and the tied-in
sutures had to be removed. The stitches pulled through the skin gave no
visible reaction. The study concluded that the presence of an implanted
biomaterial enhanced infection, but also that the experiment “led to
great diﬃculty in ﬁnding further volunteers” [7].
Since, most development pathways for novel infection-control
strategies rely largely on in vitro and pre-clinical (animal) experiments.
However, animal experiments are costly and becoming more strictly
regulated worldwide [11], while societal opposition to animal experi-
ments is growing [12]. Yet, no regulatory agency will approve new
antimicrobials without pre-clinical, animal safety data. These con-
straints have stimulated the development of highly sophisticated in vitro
methodologies, such as 3D-tissue infection [13] and organ-on-a-chip
models [14,15] and various types of co-culture methods in which
multiple key-elements of infection, including bacteria, tissue cells and
immune cells, are incorporated [16,17]. Yet, it is unlikely that an in
vitro experiment will ever completely simulate the complex and dy-
namic situation witnessed in vertebrate organisms, either animal
[10,18] or human. The use of animals in the development and valida-
tion of new antimicrobial strategies is substantial, despite the in-
creasing recognition that animal studies have a limited predictive value
for human clinical outcome, a consequence that further fuels societal
opposition [27–29]. Table 1 (largely taken from Ref. [10]) summarizes
a number of possible reasons for the limited predictive value of animal
experiments. Bacterial culturing in optimal media is a necessary step
preceding inoculation of an animal, but the transition of bacteria from
an optimal medium to an in vivo environment may have severe con-
sequences on their phenotype, with largely under-studied consequences
[10]. Often, human pathogens are selected to infect animals. Although
this may seem like a most relevant thing to do, the opposite can also be
argued since many human pathogens may not be virulent in animals
and possibly vice versa. In addition, many infections involve coloniza-
tion transitions by opportunistic pathogens to an invasive disease over
an unpredictable time-span that may well be longer than can be
maintained in animal studies. This makes novel prophylactic infection-
control strategies more diﬃcult to study in animal experiments than
therapeutic ones. Quantiﬁcation methodology is mostly geared towards
quantiﬁable numerical outcomes amenable to statistical comparison on
a continuous-scale, rather than to the binary clinical outcome of
treatment: “sick” (due to infection) or “healed”. Although continuous-
scale eﬃcacy targets can be deﬁned that bear relation with binary ef-
ﬁcacy targets for the treatment of human clinical infections, in vitro
eﬃcacy targets are generally set too low for human clinical relevance.
The consequences of inoculating an animal even with high inoculum
doses are much milder than in humans. Animal models intended to
support new infection-control strategies for chronically infected
wounds seldom deal with wounds that have been demonstrated to be
chronically infected but rather apply infected, acutely-inﬂicted wounds
that also cure without intervention. Use of young animals can only be
justiﬁed for bacterial infections in neonates or young children, but not
for elderly frequently suﬀering from immune compromise and multiple
diseases.
Many of the reasons suggested for the limited predictive value of
animal experiments are microbiological in nature and hard to
Table 1
Summary of suggested reasons in the literature for the limited predictive value of animal experiments for predicting human clinical outcome in infection-control
studies (adapted from Ref. [9]).
Animal study feature Suggested reasons for poor predictive value for human clinical outcome Reference
Bacterial inoculum preparation Bacteria are grown for inocula in optimal, complex media unlike in clinical situations. [19]
Pathogen selection Bacterial strain selection can bias results of animal studies. [20–22]
Quantiﬁcation methodology Diﬀerent methodologies yield diﬀerent outcomes; colony forming units (CFUs) as the gold standard may not always be reliable due
to non-culturable bacteria.
[23–25]
Large inoculum doses Often enormous, acute bacterial inoculum doses (106–109 CFU/site) are required for producing reliable infection in animals. [10]
Subcutaneous infection Subcutaneous infections are relatively mild compared to life-threatening tissue or organ infections in humans. [26]
Use of healthy animals Healthy, young animals are utilized, as opposed to usually elderly human patients, suﬀering immune compromise and multiple
diseases.
[10]
Eﬃcacy targets Log-3 order (99.9%) in CFU reduction or shorter presence of demonstrable numbers of pathogens are applied in animal models,
which do not reﬂect eﬃcacy targets for the treatment of human clinical infections.
[10]
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circumvent, but quantiﬁcation methodology and eﬃcacy targets in
combination with inoculum doses are intimately-related features of
animal studies that are within our control. This review aims to provide
an alternative perspective for the utility of animal infection models in
order to improve their predictive value for human clinical outcome,
focusing on study features obviously within our control. In animal in-
fections models, bio-optical imaging of bioluminescent pathogens,
sometimes supplemented with more sensitive CFU enumeration from
tissue or explanted biomaterials (the present “gold” standard), arguably
has become the most commonly applied quantiﬁcation methodology
[30,31]. First, we brieﬂy appraise pathogen-inoculum dose-ﬁnding re-
sults in animal infection models as presented in the literature. Since
published pathogen-inoculum doses are usually posed without thor-
ough description of underlying pilot studies, the appraisal is com-
plemented with results from two typical pathogen-inoculum dose-
ﬁnding pilot studies in mice involving bio-optical imaging involving
biomaterial-associated infection and meningitis. These infections were
chosen because both are severe and the human equivalent comes with
high morbidity and mortality. Results are subsequently evaluated in
view of their relevance to the human clinical outcome. Recommenda-
tions are proposed to improve the utility of animal infection models for
better translation to clinical practice and importantly, reduce numbers
of animals sacriﬁced in pre-clinical infection studies.
2. Appraisal of pathogen-inoculum dose-ﬁnding for murine
infection models
Murine infection models are most commonly reported for anti-
microbial preclinical assessment of novel infection-control strategies.
Pathogen-inoculum dose-ﬁnding for murine infection models depends
on the bacterial strain used, the quantiﬁcation methodology preferred
and the infection site [27,32–40]. Bioluminescence imaging with ge-
netically modiﬁed luminescent-enabled pathogens is nowadays used in
many studies. Upon ﬁrst introduction of bio-optical imaging for
studying infection models, bio-optical imaging was advocated as a non-
invasive quantiﬁcation methodology. It's use would reduce the numbers
of animals required, because “infection could be longitudinally monitored
in one and the same mouse” [39]. Unfortunately, in the meantime we
may arguably be able to conclude from published literature that the
opposite has likely occurred [32]. The detection limit of biolumines-
cence imaging is rather low at around 105 CFU [32]. For this reason,
many bioluminescence-based studies are supplemented with traditional
CFU enumeration. Moreover, bacterial bioluminescence depends on
metabolic activity that decreases after several days [34] and may be
aﬀected by antibiotic treatment, particularly at sub-MIC (minimal in-
hibitory concentration) levels [41]. Pathogen-inoculum dose-ﬁnding
studies usually comprise a wide dose range from 102 to 108 CFU/site.
Although 102 CFU/site has been described to be suﬃcient to invoke
reliable biomaterial-associated infections in murine knee joints for
bioluminescence imaging, higher pathogen-inoculum doses between
107 and 108 CFU/site are generally applied in other murine models.
Pathogen-inoculum doses applied may greatly depend on the biolumi-
nescent pathogen involved since host integration of a bioluminescence
construct in a stable plasmid (as e.g. in Staphylococcus aureus Xen36)
yields higher bioluminescence than direct chromosome integration (as
e.g. S. aureus Xen29) [33].
Animal losses are not always reported. A low dose of 104 CFU/site of
S. aureus ALC2906 has been reported to cause 100% loss of mice in an
evaluation of biomaterial-associated infection in the murine knee [33],
while for more frequently applied S. aureus Xen29, 100% loss of ani-
mals has been reported to occur at a 4 log-unit higher dose of 108 CFU/
site [36]. Also 15–30% loss of animals has been reported for sub-
cutaneous Pseudomonas aeruginosa PA14 at doses between 107 and
108 CFU/site [34], while a lower dose of 106 CFU/site caused 100% loss
of animals when the pathogen selected was P. aeruginosa Xen5 [36].
Since pathogen-inoculum dose-ﬁnding pilot studies are not always
described in suﬃcient detail to understand the precise rationale for
deciding on a given pathogen-inoculum dose in further larger-powered
studies, we report in addition to the studies cited above, on results of
two (unpublished) pathogen-inoculum dose-ﬁnding pilot studies in
mice (see Supporting Information for experimental details) involving
diﬀerent types of infection.
One dose-ﬁnding pilot study was performed as part of a larger-
powered animal infection-control experiment, in which antimicrobial
eﬀects of a DNaseI coating [42] on peri-operative infections associated
with implanted biomaterials were evaluated. This dose-ﬁnding pilot
study de facto represents an animal analogue of the Elek-experiment in
humans, but evaluating infection associated with implanted titanium-
discs based on bio-optical imaging. Beyond the pilot study presented
here, results of the larger-powered animal experiment were considered
inconclusive and never published, presumably because improper deci-
sions were made based on the dose-ﬁnding pilot study.
Fig. 1 summarizes examples of bioluminescence images of mice in
the diﬀerent groups of animals without and with an implanted tita-
nium-disc in the absence or presence of diﬀerent pathogen-inoculum
doses of bio-luminescent S. aureus Xen36, taken during the initial days
after disc implantation and pathogen inoculation of the animals.
Clearly, an inoculum dose of 107 staphylococcal CFU/site constituted
too low a dose to image in situ growth of bioluminescent S. aureus
Xen36. More substantial doses of 108 or 109 staphylococcal CFU/site
yielded clear images of the progression of infection over time, while
also showing that the implanted titanium-discs exacerbated the infec-
tion, especially in mice infected with 109 staphylococcal CFU/site.
Fig. 2 presents survival curves for the diﬀerent groups of mice. All
mice without an implanted titanium-disc survived the experimental
Fig. 1. Examples of IVIS (In Vivo Imaging System) dark box, bioluminescence
images of mice, infected with diﬀerent inoculum doses of bioluminescent S.
aureus Xen36 taken directly and then at day 2 and 4 after injection of a sta-
phylococcal suspension (20 μL) in the absence and presence of an implanted
titanium-disc. Staphylococcal injection onto the implanted titanium-disc sur-
face occurred after surgical-closure of the wound.
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period without any signs of infection or other adverse side-eﬀects, re-
gardless of pathogen-inoculum dose. However, mice with an implanted
titanium-disc and inoculated with the highest dose of 109 staphylo-
coccal CFU/site presented with purulent wounds near the implant site,
consistent with the bioluminescence images in Fig. 1. This infection
caused loss of one animal at day 3 and eventual loss of all animals at
day 18 after pathogen inoculation. Inoculation with a dose of 108 sta-
phylococcal CFU/site led to the loss of 1 animal at day 14 in the tita-
nium-implant group, while all animals with an implanted titanium-disc
injected with an inoculation dose of 107 staphylococcal CFU/site sur-
vived.
Fig. 3 shows that the bioluminescence ﬂux arising from mice in-
oculated with a dose of 107 staphylococcal CFU/site was only slightly
higher than from mice inoculated with sterile saline during the ﬁrst six
days after implantation and inoculation. Diﬀerences in bioluminescence
from mice inoculated in both absence and presence of implanted tita-
nium-discs were negligible. When inoculated with dose of 108 staphy-
lococcal CFU/site, mice readily cleared pathogen inoculation in absence
of an implanted titanium-disc to saline-control levels within 10 days. In
the presence of implanted titanium-discs, however, bioluminescence
remained well above control levels until the end of the study at day 28.
Yet the three surviving animals out of the group of four, exhibited no
clinical symptoms of infection. Natural clearance of infection according
to bioluminescence output by the mouse immune system in the absence
of an implanted titanium-disc at a dose of 109 staphylococcal CFU/site
to saline-control levels occurred slower than at lower doses but still
occurred within 18 days after implantation and inoculation and without
loss of animals (compare Fig. 2). However, at the highest inoculum dose
of 109 staphylococcal CFU/site and in the presence of an implanted
titanium-disc, bioluminescence was only marginally higher in the tita-
nium-implant group than in the group of mice without an implant.
However, infection-associated complications necessitated termination
of this experimental group at day 18 (see also Fig. 2). Based on this
pathogen-inoculum dose-ﬁnding pilot study, the dose of 107 staphylo-
coccal CFU/site was considered too low for reliable infection-control
evaluation. The high loss of animals/implants at the highest dose of 109
staphylococcal CFU/site was considered experimentally unacceptable
for various reasons, such as an unpredictable number of surviving mice
at end-point and inhumane animal morbidity arising from infection,
requiring termination of the animal. Summarizing, we concluded, si-
milar to virtually all pathogen-inoculum dose-ﬁnding pilot studies for
infection-control evaluation in mice, that an inoculum dose of 107
staphylococcal CFU/site was too low to yield any useful outcome
parameter, while a dose of 109 staphylococcal CFU/site yielded too
many losses for appropriate powering of the study. Accordingly, the
decision was made to apply an intermediate pathogen-inoculation dose
of 108 staphylococcal CFU/site, which in a larger-powered murine
study presumably led to inconclusive results.
A second dose-ﬁnding study (see also Supporting Information for
experimental details), was carried out as part of a larger-powered an-
imal infection-control experiment evaluating a new antimicrobial for
the control of meningitis. Bacterial meningitis is an extremely serious
infection of the brain. Escherichia coli is one of the Gram-negative pa-
thogen causing meningitis, in particular during the neonatal period
where it is the second most common causative agent [43]. Rapid di-
agnosis is paramount in conjunction with eﬃcacious antibiotic therapy,
otherwise morbidity and often mortality is inevitable within days after
the onset of the ﬁrst symptoms [44]. All mice, regardless of the E. coli-
inoculum dose injected into the brain, awoke within 1–2 h after in-
oculation and anesthesia without showing any signs of morbidity (see
Table 2) or other signs of distress. At the lowest pathogen-inoculum
dose of 2.5 × 102 E. coli CFU/site, mice demonstrated no signs of
morbidity, while at a higher dose of 2.5 × 103 E. coli CFU/site signs of
morbidity disappeared over the course of 48 h. Similarly, at a dose of
Fig. 2. Kaplan-Meier survival curves for mice inoculated with diﬀerent doses of
bioluminescent S. aureus Xen36 as a function of time after infection in the
absence and presence of an implanted titanium-disc. Each group comprised four
mice. Mice were terminated when their condition had reached a pre-deﬁned,
humane endpoint, or completion of the study at the designated end of the ex-
periment (day 28).
Fig. 3. Bioluminescence ﬂuxes in mice, inoculated with diﬀerent doses of
bioluminescent S. aureus Xen36 as a function of time after inoculation in the
absence and presence of an implanted titanium-disc. The diﬀerently colored,
shaded areas indicate the eﬀects of inoculation in absence of an implanted ti-
tanium-disc with respect to the saline-control (no injected staphylococci; light-
shaded), while the dark-shaded areas represent the eﬀects of an implanted ti-
tanium-disc on infection. Error bars indicate the standard error of the mean
over the number of surviving mice in each group (see Fig. 2).
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2.5 × 104 E. coli CFU/site, mice began to eat and drink again after 48 h,
which may have alluded the onset of complete disappearance of mor-
bidity and full clearance of infection. Only the highest dose of
2.5 × 105 E. coli CFU/site, persistent morbidity signs were observed in
conjunction with mortality in all mice, which is the typical course of
meningitis in humans when left untreated. Bioluminescence imaging
(Fig. 4) revealed absence of bioluminescence at the lowest E. coli-
inoculum dose, but with noticeable bioluminescence in mice inoculated
with higher doses. Mice injected with the highest pathogen dose
showed the highest bioluminescence. Contrary to the decision taken in
the biomaterial-associated infection pilot study, it was here decided to
apply the highest pathogen-inoculation dose of 2.5 × 105 E. coli CFU/
site for further studies, because the course of infection then proceeded
comparably with human clinical symptoms of untreated meningitis.
Table 2
Signs of morbidity and mortality in diﬀerent groups of six mice, with diﬀerent E. coli-inoculum doses injected (2.5 μL) in the brain.
Hours after inoculation 2.5 × 102 CFU/site 2.5 × 103 CFU/site 2.5 × 104 CFU/site 2.5 × 105 CFU/site
Deatha
12 −a – – 3/6b
24 – – – 5/6
48 – – – 6/6
Lethargyc
12 + + + +
24 + + + +
48 – + + f
Not Eatingc
12 + + + +
24 – – + +
48 – – – f
Scarcely Drinkingc
12 + + + +
24 – – + +
48 – – – f
Reduced Movement/Leaning over to One Side of the Bodyc
12 + + + +
24 – – + +
48 – – + f
Feverishd
12 – +++ +++ +++
24 – ++ +++ +++
48 – + +++ f
Loss of Body Weighte
12 + ++ +++ +++
24 + ++ +++ +++
48 + ++ +++ f
Photophobicc
12 – – + +
24 – – + +
48 – – + f
Abnormal Behaviourc
12 + + + +
24 + + + +
48 – + + f
a Indicates absence of the described symptom.
b Number of dead mice in a group of six.
c Symptoms were displayed by all mice in a group.
d +++: temperature above 38.5 °C, ++: temperature between 38 °C and 38.5 °C, +: temperature between 37.5 and 38 °C, -: temperature less than 37.5 °C.
e +++: weight loss more than 2.5 g, ++: weight loss between 2.5 and 1.5 g, +: weight loss less than 1.5 g.
f No surviving mice.
Fig. 4. Examples of IVIS dark box, bioluminescence images of mice, infected in the brain with diﬀerent inoculum doses (2.5 μL) of bioluminescent E. coli Xen14 taken
48 h after brain-injection. Mice injected with a dose of 2.5 × 105 E. coli CFU/site died prior to bioluminescence imaging.
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3. Discussion
Bacterial bioluminescence in mice decreased over time in the ab-
sence or presence of an implanted titanium-disc after pathogen in-
oculation (Fig. 3), exactly following expectations for biomaterial-asso-
ciated infection [44]. This pathogen-inoculum dose-ﬁnding pilot study
can be considered as the complete murine analogue of the Elek-ex-
periment in humans [7], now carried out with modern evaluation
methods. However, the magnitude of bacterial bioluminescence de-
creases over time, depended heavily on pathogen-inoculum dose, si-
milar as in the meningitis dose-ﬁnding pilot study. Virtually all deci-
sions on pathogen-inoculum doses follow the same pattern of
considerations in murine and other animal infection models. Un-
fortunately, pathogen-inoculum dose-ﬁnding pilot studies seldom re-
port the considerations underlying any decision for selecting a speciﬁc
pathogen-inoculum dose in detail. Yet, the choice for a particular pa-
thogen-inoculum dose may critically aﬀect the predictive value of a pre-
clinical animal experiment for human clinical outcome in pursuing
larger-powered studies. Below, we debate the question of whether we,
and many of our peers, used the correct arguments to decide for in-
termediate doses of around 108 CFU/site, as in our dose-ﬁnding pilot
study on peri-operative infections associated with implanted bioma-
terials. An alternative and more unusual decision was taken in our
study on meningitis, in which a high, lethal dose of 2.5 × 105 E. coli
CFU/site was decided upon, causing death of all mice within 48 h.
Arguments and counter-arguments for both decisions are presented
below:
3.1. Intermediate pathogen-inoculum doses should be used that avoid
animal death
The intermediate staphylococcal-inoculum dose in the biomaterial-
associated infection model left us a broad experimental window to
evaluate possible eﬃcacy of a new infection-control coating, yielding
large bioluminescence diﬀerences between control and infected groups.
Important for publication purposes, loss of animals during the experi-
mental period was expected to be small and inhumane, infection-as-
sociated morbidity of animals to be minimal. Ethical and practical as-
pects common to many experimental designs were prospectively
satisﬁed. A lethally high E. coli-inoculum dose as preferred in the me-
ningitis model, does not allow all this and should not be chosen.
3.2. High, lethal pathogen-inoculum doses should be considered preferable
Animal experiments should be directly relevant for the human
clinical situation and if they do not meet this condition, they should not
be allowed or performed. Humans seek medical intervention when they
feel ill. In severe cases for which our research endeavours seek to
provide help, infection causes people to become lethargic, they do not
eat, scarcely drink, hardly move and develop fever, all of which inﬂu-
ence the body's ability to ﬁght the infection. Commonly, a bacterial
infection causes drainage, acute organ failure or necessitates immediate
life-saving intravenous antibiotic administration or surgery on a heavily
suﬀering patient. If mis-diagnosed or wrongly treated, patients die
within days from serious infections, like meningitis [45] or a bioma-
terial-associated infection like endocarditis, which can arise from a
simple pacemaker replacement [46]. A relevant animal experiment
should mimic this worst case, clinical courses, including death. The
number of annual deaths worldwide due to antimicrobial resistant in-
fection amounts currently around 700,000 [1], and is expected to rise
to 10 million by the year 2050 [47] when severe infection may have
become the clinical norm. Current research and associated animal use,
should be primarily aimed towards preventing just this from becoming
true.
The ultimate objective of clinical intervention is to prevent death
and recurrence of infection. This rationale would support the choice for
the most aggressive model and highest possible pathogen-inoculation
dose for both studies discussed above. Prevention of animal death and
recurrence of infection as primary eﬃcacy targets would yield a more
robust study with higher translational relevance when compared to
aiming for statistically signiﬁcant reductions in bioluminescence, CFUs
or number of days over which infection is present, as most current
studies report.
Taking prevention of death as a critical, primary eﬃcacy target
requires accepting what might be considered as high levels of animal
morbidity and mortality and undoubtedly invoke the highest degree of
scrutiny by animal welfare review bodies. However, animal morbidity
can be alleviated using pain medication, which will actually add to the
resemblance between infection in test animals and humans and there-
with to the predictive value of the animal experiment. After all, no
expert knows the clinical relevance of a reduced bioluminescence, less
CFUs or more rapid clearance of infection, while most animals are also
able to clear intermediate inoculum dose infections without interven-
tion. Infection models in animals are seldom designed to allow mor-
bidity and to have death as an end-point to be prevented by a novel
treatment. Yet, it can be argued that this much more closely resembles
the human situation of a seriously ill person seeking medical care than
an animal that is infected to a level that is not morbid, self-clearing and
observably hardly bothersome.
As another primary eﬃcacy target, in cases where a new strategy
prevents animal death, animals should no longer be sacriﬁced at the
pre-designated end of an experimental period, but instead be followed
longitudinally over time to evaluate possible recurrence of infection.
Recurrence is a troublesome complication of human clinical infection
treatment. Recurrence arises from incomplete eradication of infectious
bioﬁlms and infecting pathogens seeking shelter in mammalian cells
against antibiotic treatment [48,49]. Prevention of recurrence as a
second primary eﬃcacy target in evaluating novel infection-control
strategies will likely also add to the predictive value of animal experi-
ments for human clinical outcome, but may go at the expense of e.g.
other end-point evaluations such as histology or bacterial CFUs in
tissue. In the authors opinion, opting for 1) lethally high pathogen-in-
oculum doses with death and 2) recurrence of infection as preventable
primary eﬃcacy targets, is preferable, simply because death, morbidity
and recurrence are unequivocally associated with the human disease
symptoms of infection.
Turning the emphasis of infection-control studies to death and re-
currence as primary eﬃcacy targets, reduces the impact of quantiﬁca-
tion methodology (see Table 1) on the ﬁnal conclusions of a study. Yet,
other secondary eﬃcacy targets such as reduced bioluminescence,
faster clearance of infection in animal models or end-point bacterial
CFU reduction in tissue and histology, may remain useful to improve
our understanding of pathogenesis and infection mechanisms, as well as
of healing processes occurring upon application of novel infection-
control strategies. However, these should only be pursued without ad-
ditional inconvenience or costs of animal lives. In this respect, bio-op-
tical imaging remains a good assay, because it is non-invasive and al-
lows monitoring the course of infection over time in one and the same
animal. However, as a drawback of bio-optical imaging, it should be
kept in mind that bio-optical imaging limits pathogen selection (see
Table 1) due to the relatively few bioluminescent strains available.
The above suggestion to base infection-control studies in animals
primarily on death as an endpoint and recurrence of infection, requires
serious diligence to address the increased morbidity. It is clear that to
date, that prior to starting human clinical trials, animal experiments are
still required to investigate new, infection-control strategies for the
occurrence of possible adverse eﬀects using vertebrate animals.
Unforeseen problems upon application of new, infection-control stra-
tegies in humans, as in the 1957 Elek-experiment [7], must be mini-
mized. Few would argue to move novel infection-control strategies to
human clinical trials without animal de-risking. Nonetheless, animal
experiments conducted solely upon demands of peer reviewers and
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editors of high impact journals with the mere aim to get papers pub-
lished, should be prohibited. The idea that good, well-founded infection
research must always, necessarily involve animal studies is presumed
too often and animal studies have become the routine default position
for infection research and development without proper justiﬁcation.
Also, when the work has little prospects of downward clinical transla-
tion (i.e. because it represents far too complicated methodology, im-
possible to produce cost-eﬀectively, cannot be sterilized, or lack of
commercial interest or funding), animal experiments should not be
conducted. We believe that the amount of animal use for demonstration
of mechanisms is excessive, often experimentally unjustiﬁed and largely
without merit or impacting conclusions. Ample, highly sophisticated in
vitro models are available nowadays [13–17] to establish beneﬁt over a
clinical standard and provide clues and guidance to elucidate me-
chanisms of action of new antimicrobials, warranting scientiﬁc pub-
lication in the absence of pre-clinical animal evaluation. Animal ex-
periments should only be employed once in vitro research has clearly
demonstrated beneﬁt over the clinical standard of treatment for a
particular type of infection and not for demonstration of mechanisms of
action. Moreover, it seems trivial to this authors consortium, not to
dedicate much concern, signiﬁcant research resources, and animal lives
on self-resolving infections or those curable with current therapies.
In conclusion, this consortium suggests the use of higher animal
morbidity models in exchange for sacriﬁcing fewer animals in the de-
velopment of novel infection-control strategies in order to perform
animal assessment of novel strategies with a greater predictive value for
human clinical outcome. Speciﬁcally, our suggestions involve:
1. acceptance of animal death and recurrence of infection as primary
eﬃcacy targets,
2. considering other infection quantiﬁcation methodologies such as
bio-optical imaging or CFU analysis only as secondary eﬃcacy tar-
gets, provided this can be accomplished without additional incon-
venience or costs of animal lives,
3. only allowing animal evaluation of novel infection-control strategies
when in vitro experiments have indicated superiority above the
clinical standard of treatment,
4. restricting animal experiments to elucidate mechanisms of action of
a new antimicrobial when eﬀective in vitro models are available.
These suggestions are put forward with the best intentions towards
making animal experiments more useful for predicting human clinical
outcome and translating novel infection-control strategies to clinical
use. This will create better de-risking and may help in accelerated
translation of new infection-control strategies to clinical use.
Furthermore, the authors intend to curb unnecessary studies resulting
in preventable animal usage for the sake of science only. We will do our
utmost best to perform research that meets the above suggestions, in
which we sincerely believe. Nevertheless, our scientiﬁc curiosity drives
us. May our scientiﬁc curiosity kill neither the cat nor the mouse and
save human lives.
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